Phosphorylated α-Synuclein-Copper Complex Formation in the Pathogenesis of Parkinson’s Disease

Juan Antonio Castillo-Gonzalez,1 Maria De Jesus Loera-Arias,1 Odila Saucedo-Cardenas,1,2 Roberto Montes-de-Oca-Luna,1 Aracely Garcia-Garcia,1 and Humberto Rodriguez-Rocha1

1Departamento de Histología, Facultad de Medicina, Universidad Autónoma de Nuevo León, 64460 Monterrey, NL, Mexico
2Centro de Investigaciones Biomedicas del Noreste, Monterrey, NL, Mexico

Correspondence should be addressed to Humberto Rodriguez-Rocha; humberto.rodriguezrc@uanl.edu.mx

Received 23 August 2017; Accepted 11 October 2017; Published 23 November 2017

Copyright © 2017 Juan Antonio Castillo-Gonzalez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Parkinson’s disease is the second most important degenerative disorder worldwide. It is characterized by the presence of Lewy bodies, which are mainly composed of α-synuclein and ubiquitin-bound proteins. Both the ubiquitin proteasome system (UPS) and autophagy-lysosomal pathway (ALS) are altered in Parkinson’s disease, leading to aggregation of proteins, particularly α-synuclein. Interestingly, it has been observed that copper promotes the protein aggregation process. Additionally, phosphorylation of α-synuclein along with copper also affects the protein aggregation process. The interrelation among α-synuclein phosphorylation and its capability to interact with copper, with the subsequent disruption of the protein degradation systems in the neurodegenerative process of Parkinson’s disease, will be analyzed in detail in this review.

1. Introduction

Parkinson’s disease (PD) is the second most frequent neurodegenerative disorder related to aging worldwide [1]. The clinical symptoms of this disease are resting tremor, rigidity, bradykinesia, akinesia, postural instability, difficulty in speech, and breathing problems [2]. Most PD cases appear to be sporadic, and only about 5–10% of the cases are due to genetic mutations [3]. Exposure to environmental pollutants such as herbicides (paraquat), pesticides (rotenone), and toxic substances during the manufacture of narcotic drugs (MPTP) and prolonged exposure to transition metals have been reported to be related to sporadic cases of PD [4–6]. PD is characterized by dopaminergic neuronal loss in the substantia nigra at the central nervous system (CNS), a significant reduction in dopamine levels, and the presence of Lewy bodies [7, 8]. Lewy bodies are composed of abnormal deposits of protein aggregates, particularly α-synuclein and ubiquitin-bound proteins [9]. Abnormal protein aggregation results from the UPS and ALS alteration, and the latter includes disruption of lysosomal hydrolase trafficking [10–12]. Interestingly, some metal ions such as copper have shown to promote the protein aggregation process [13–15]. Additionally, phosphorylation of α-synuclein, along with copper, accelerates the protein aggregation process [16, 17].

Therefore, in order to have a better understanding of the mechanisms involved in the neurodegenerative process of PD, the interrelation among α-synuclein phosphorylation and its capability to interact with copper, as well as the consequent disruption of the protein degradation systems, will be analyzed in detail in this review.

2. α-Synuclein

The main histological hallmark of PD is the presence of eosinophilic cytoplasmic inclusions known as Lewy bodies, which are localized in the substantia nigra and are formed mostly by α-synuclein [18–20]. α-Synuclein is a thermostable, preserved, and unfolded cytosolic protein [21], belonging to a family of homologous proteins called synucleins, and
is expressed in approximately 80% of the total area of the human brain [22, 23]. α-Synuclein consists of 140 amino acid residues [24] organized in three structural regions: an amphipathic amino-terminal domain from 1 to 60 amino acid residues, responsible for the binding of α-synuclein to lipid vesicles [25, 26]; the NAC (non-amyloid-β component) region from 61 to 95 amino acid residues, also found in amyloid plaques of patients suffering from Alzheimer’s disease [27] and responsible for α-synuclein aggregation and β sheets arrangement [28]; and the carboxy-terminal domain from 96 to 140 amino acid residues, which is the main target for the protein phosphorylation [29, 30] (Figure 1(a)). α-Synuclein is primarily expressed in neurons at cytosolic level and is abundant in presynaptic terminals [31]. However, it has also been linked to synaptic vesicles, plasma membrane lipid rafts and the nucleus [32]. Up to date, the main normal function of α-synuclein has not been well defined. α-Synuclein has been related to different functions, including inhibition of tyrosine hydroxylase [33], inhibition of dopamine release [34], dopamine uptake [35], neural plasticity, synaptic maturation and maintenance [36–38], and v-SNARE complex assembly [39, 40].

α-Synuclein has the capability to assemble into amyloid fibers, soluble oligomers, and/or aggregates. Once the accumulation of α-synuclein surpasses its degradation rate, it leads to the formation of Lewy bodies and the subsequent death of dopaminergic neurons in the substantia nigra [41]. It has been suggested that α-synuclein protofibrils are responsible for the neurotoxic effects induced by α-synuclein [42, 43]. Among the possible mechanisms involved in the neurotoxicity mediated by α-synuclein are the following: mitochondrial dysfunction, oxidative stress [44], lysosomal leakage [45], cytoskeletal disruption [46], altered axonal transport, and subsequent synapses dysfunction, which are all related to neurodegeneration [47]. α-Synuclein is targeted for degradation by the UPS and the ALS including the chaperone-mediated autophagy (CMA) and macroautophagy (autophagy) [48–51]. Importantly, both degradation pathways are dysregulated or inhibited in PD [52].

The relationship between α-synuclein and PD was established with the identification of specific mutations in the SNCA gene encoding for α-synuclein, in families with PD. The specific mutations identified in α-synuclein were a substitution from alanine to threonine at amino acid residue 53 (A53T), a mutation of Greek origin [53]; a substitution from alanine to proline at amino acid residue 30 (A30P), a mutation of Germanic origin [54]; and a substitution from glutamic acid to lysine at amino acid residue 46 (E46K), a mutation of Spanish origin [55] (Figure 1(a)). Recently, two new mutations have been identified, a substitution from histidine to glutamine at amino acid residue 50 (H50Q) [56] and a substitution from glycine to aspartic acid at amino acid residue 51 (G51D), a mutation of French origin [57]. Additionally, SNCA gene duplication [58] and triplication also occur and are related to PD [59].

3. α-Synuclein Phosphorylation in Parkinson’s Disease: Neuroprotective or Neurotoxic?

In the aggregation process of α-synuclein, its phosphorylation plays an important role [29, 60] by directing its localization and interaction [61] and by modifying its secondary
Figure 2: Cell alterations involved in the aggregation process of α-synuclein. Damaged or unrequired proteins are regulated by both the proteasomal and lysosomal degradation pathways. UPS disruption leads to activation of the ALS and vice versa, as a compensation mechanism. Both mechanisms are affected in PD, which results in protein accumulation including α-synuclein and ubiquitin-bound proteins. Accumulation of unfolded or misfolded proteins into the endoplasmic reticulum activates the unfolded protein response. Mitochondrial dysfunction and oxidative stress are also interrelated and linked to the pathogenesis of PD. All these alterations are associated with the phosphorylation process of α-synuclein and increase α-synuclein oligomerization, leading to Lewy body formation and subsequent apoptotic cell death.

and tertiary conformation [62–65]. α-Synuclein is targeted by phosphorylation on multiple sites located at its carboxy-terminal end (S87, S129, Y125, Y133, and Y136) [66–71] (Figure 1). Several kinases have been linked to α-synuclein phosphorylation, such as casein kinases 1 and 2 (CK1 and CK2), G protein-coupled receptor kinases 2 and 5 (GRK2 and GRK5), polo-like kinase 2 (PLK2) [29, 72, 73], Fyn [74], and more recently serine/threonine protein kinase (LK6) and MAP kinase-interacting kinase 2a (Mnk2a) [75].

Studies performed in cell cultures with neuronal phenotype have demonstrated that CK2-mediated α-synuclein phosphorylation, particularly at S129, increases the appearance of eosinophilic cytoplasmic inclusions resembling the Lewy bodies of PD [76]. A major component of these inclusions consists of C-terminally truncated α-synuclein, and lysosomal proteases, such as cathepsin D, may be involved in its production for α-synuclein oligomerization [77]. Some mechanisms are triggered by the phosphorylation of α-synuclein, including the unfolded protein response (UPR) and disruption of lysosomal degradation pathways, which may lead to protein aggregation and subsequently to cell death (Figure 2) [78, 79]. Monomers and dimers of α-synuclein are degraded by ALS, specifically, CMA [79, 80]. In addition, it has been reported that a phosphorylated-like mutant version of α-synuclein (S129E), which mimics the biochemical and biophysical properties of α-syn phosphorylation observed in PD patients’ brains [76] and remained “phosphorylated-like” after exposure to the lysosomal fraction, cannot translocate across the lysosomal membrane probably because of a conformational change induced by its phosphorylation, decreasing its interaction with the CMA receptor (LAMP-2A) at the lysosomal membrane [79, 80].

In addition, dysfunctional mitochondrial metabolism and increased ROS production are also related to the
Phosphorylation of α-synuclein (Figure 3) [81]. Hydrogen peroxide- (H₂O₂-) induced oxidative stress increases the phosphorylation of α-synuclein at S129 and the formation of cytoplasmic inclusions [76]. On the other hand, some neurotoxins and the UPS inhibition increase the activity of GRK5 and CK2, whose interaction with Ca²⁺/calmodulin increases α-synuclein phosphorylation at S129 [82–84]. Rotenone, an inhibitor of mitochondrial complex I, along with iron, increases the levels of α-synuclein phosphorylation at S129, by inducing ROS production in dopaminergic cells [81].

So far, the role of α-synuclein phosphorylation is controversial. Some studies have shown a neuroprotective role of α-synuclein phosphorylation at S129 by preventing the binding of α-synuclein oligomers to membranes and, therefore, cellular disruption [85–88]. Additionally, phosphorylation at S129 blocked α-synuclein fibrillation in vitro [89]. Many studies had focused on the role of α-synuclein phosphorylation, specifically at S129, and also at other residues such as S87. α-Synuclein mutant variants, capable of mimicking or inhibiting the phosphorylation process (S129D, S129E, and S129A), have contributed to the elucidation of its role [66, 70, 89–92]. Phosphomimic mutants S129D/E were not able to reproduce in vitro the structural and aggregation properties of α-synuclein. However, a nonphosphomimic mutant S129A showed a higher protein aggregation rate and neurotoxicity than the wild type form [70, 71, 89].

On the contrary, there is evidence showing that α-synuclein phosphorylation at S129 induces cytotoxicity [66, 77, 93, 94]. It has been demonstrated that α-synuclein phosphorylation at S129 mediated by CK2 is an important factor for its protein aggregation and toxicity, inducing UPR dysregulation, endoplasmic reticulum (ER) stress, and apoptosis [78]. Besides, phosphorylation at S129 is essential for interaction of α-synuclein with synphilin-1 and parkin,
which form the ubiquitinated inclusions [76]. Recently, it has been reported that α-synuclein can also be phosphorylated by LK6 and Mnk2a, with subsequent dopaminergic neuronal death and formation of cytoplasmic inclusions, respectively [75]. Nonetheless, it has been suggested that malfunction of the UPS increases CK2 activity, resulting in hyperphosphorylation of the α-synuclein at SI29 [95].

Approximately 90% of α-synuclein detected in Lewy bodies from postmortem PD samples is phosphorylated at SI29. Conversely, only 4% of α-synuclein present in normal brains is phosphorylated [66, 70, 96, 97]. Importantly, a mass spectrometry study in human cerebrospinal fluid (CSF) of PD and other parkinsonian disorders determined a significantly higher concentration of phosphorylated α-synuclein at SI29, as well as a significant increase in the ratio of phosphorylated α-synuclein at SI29 to total α-synuclein in PD compared to healthy controls [98]. More recently, a marked difference between PD patients and healthy controls was observed with a sensitive and specific Elisa test, by combining measurements of total, oligomeric, and phosphorylated (SI29) α-synuclein in CSF [99].

4. Interaction of Phosphorylated α-Synuclein with Metal Ions

Proteins are the main biomolecules affected in most pathologies; posttranslational modifications of proteins suchlike oxidation, nitration, carbonylation, glutathionylation, and phosphorylation are related to protein inactivation. Phosphorylated proteins have a strong binding affinity to certain metals [16, 100, 101]. Multivalent metal ions, like manganese, cobalt, iron, and mainly aluminum and copper, increase α-synuclein fibril formation by inducing conformational changes [14, 102, 103]. α-Synuclein may interact with different metal ions at either its carboxy-terminal domain or its amino-terminal domain, depending on the metal ion concentration [13]. For instance, at low concentrations (40–100 μM) Cu²⁺ ion binds to the amino-terminal domain [13, 104], while at extremely high concentrations (0.5–5 mM), which are unlikely to occur in tissues, metal ions such as Fe²⁺, Mn²⁺, Ni²⁺, Co²⁺, and Cu²⁺ bind to the carboxy-terminal domain [105]. Cu²⁺ ion is a potent inducer and accelerator of α-synuclein aggregation, linked to the carboxy-terminal domain, which is required for its oligomerization [106]. Phosphorylation at both Y125 and SI29 residues of α-synuclein, which are close to metal-binding sites, increments Cu²⁺, Pb²⁺, and Fe²⁺ binding capability to carboxy-terminal domain (Figure 1) [17, 105].

5. Copper Mediates α-Synuclein Aggregation

On the other hand, copper has the ability to inhibit the proteasomal chymotrypsin-like peptidase activity [107]. Copper enters into the cell through the copper transporters 1 and 2 (CTR1 and CTR2), which are located on the cell membrane (Figure 3) [108]. Two regions, 1MDVFMKGLS⁵ and 48VWGV⁵² (Figure 1), with high-affinity binding sites for copper were identified in α-synuclein, and may be of great biological importance in the pathogenesis of PD [104]. Within the α-synuclein sequence, methionine I and histidine 50 residues function as independent anchoring sites for copper binding (Figure 1) [104, 109, 110].

There are three models that have been suggested for copper binding to α-synuclein (Figure 3). In the first model, a single α-synuclein molecule binds to Cu²⁺, folding and bringing together the amino and carboxy-terminal regions. The second model involves two molecules of α-synuclein with a head-to-tail arrangement, generating a copper-binding site at both ends. In the third model, α-synuclein oligomerization takes place by interaction of the carboxy-terminal region of one molecule of α-synuclein with the amino-terminal region from a second molecule of α-synuclein originating a Cu²⁺ binding site; then a second Cu²⁺ binding site is formed by interaction of one of the two α-synucleins with a third α-synuclein molecule [15].

Regarding the aggregation process of α-synuclein mediated by copper, two mechanisms have been proposed. In one of them, high levels of α-synuclein-copper complexes will cause instability of intramolecular interactions leading to self-assembling of α-synuclein into fibrillar complexes. In the second one, copper redox-mediated reactions induce oxidation of α-synuclein using electron donors (NADH, NADPH, glutathione, etc.), causing its oligomerization and precipitation [111–114].

Environmental exposure to metal ions (e.g., zinc and copper) induces α-synuclein aggregates and oxidative stress, which are also associated with dysregulation of the UPS in PD [82, 115, 116].

Copper plays a dual role in the neurotoxic effect of α-synuclein. Once intracellular copper concentration is raised, chaperone proteins (e.g., ATOX1, CCS, MT3, and COX17) are in charge to uptake this metal inside the cell, but an overload of copper might surpass the chaperone proteins available to regulate its levels. On the other hand, mutations affecting the ability of chaperones to bind copper might also increase its toxic effect [117]. Subsequently, free copper binds to the UPS to inhibit its activity; then α-synuclein is phosphorylated increasing its affinity to metals [71]. α-Synuclein-copper complex formation alters cell redox signaling, which results in ROS formation including H₂O₂, H₂O₃ oxidizes dopamine, which is toxic to dopaminergic neurons [118, 119].

6. Concluding Remarks

α-Synuclein is a highly relevant protein in PD etiopathology, and since the elucidation of α-synuclein-copper interactions, this transition metal was brought into the spotlight of neurodegeneration research. Although this complex formation is now subject of intense research, many open questions remain: How are levels of copper regulated by α-synuclein? Does copper influence α-synuclein phosphorylation and aggregation? How important is copper and α-synuclein interaction? Can we use phosphorylation of α-synuclein as a biomarker? Can we exploit the inhibition of phosphorylation of α-synuclein as a therapeutic approach? It is certain, that these therapies need to initiate promptly in order to address pathological
changes in a less advanced stage. Regrettably, the diagnosis of PD nowadays is based on purely clinical signs, and these signs are manifested when more than half of dopaminergic neurons have died. Therefore, identification of early biomarkers such as α-synuclein phosphorylation may be a promising approach for diagnosis and subsequently for PD treatment and correlated with preclinical signs indicating incipient disease at this stage. Since α-synuclein and copper play such important roles in the aggregation process, a chelator administration is currently under investigation and may be a helpful approach against PD.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This work was supported by the National Council of Science and Technology (CONACYT) CB-2013-221615 (Aracely Garcia-Garcia) and Program for the Professional Development of the Professors (PRODEP) DSA/103.5/14/11175 (Humberto Rodriguez-Rocha). Juan Antonio Castillo-Gonzalez received a scholarship from CONACYT.

References

[1] K. Wirdefeldt, H. Adami, P. Cole, D. Trichopoulos, and J. Mandel, "Epidemiology and etiology of Parkinson's disease: a review of the evidence," European Journal of Epidemiology, vol. 26, supplement 1, pp. S1–S58, 2011.

[2] L. S. Forno, "Neuropathology of Parkinson's disease," Journal of Neuropathology & Experimental Neurology, vol. 55, no. 3, pp. 259–272, 1996.

[3] S. Lesage and A. Brice, "Parkinson's disease: from monogenic forms to genetic susceptibility factors," Human Molecular Genetics, vol. 18, no. RI, pp. R48–R59, 2009.

[4] B. C. L. Lai, S. A. Marion, K. Tesche, and J. K. C. Tsui, "Occupational and environmental risk factors for Parkinson's disease," Parkinsonism & Related Disorders, vol. 8, no. 5, pp. 297–309, 2002.

[5] J. Peng, L. Peng, F. F. Stevenson, S. R. Doctrow, and J. K. Andersen, "Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson's disease accelerate age-related neurodegeneration," The Journal of Neuroscience, vol. 27, no. 26, pp. 6994–6922, 2007.

[6] K. Opeskin and R. M. Anderson, "Suspected MPTP-induced parkinsonism," Journal of Clinical Neuroscience, vol. 4, no. 3, pp. 366–370, 1997.

[7] C. W. Shults, "Lewy bodies," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 6, pp. 1661–1668, 2006.

[8] O. Hornykiewicz, "The discovery of dopamine deficiency in the parkinsonian brain," Journal of Neural Transmission. Supplementa, vol. 70, pp. 9–15, 2006.

[9] M. S. Pollanen, D. W. Dickson, and C. Bergeron, "Pathology and biology of the lewy body," Journal of Neuropathology & Experimental Neurology, vol. 52, no. 3, pp. 183–191, 1993.

[10] C. Cook, C. Stetler, and L. Petrucelli, "Disruption of protein quality control in Parkinson's disease," Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 5, Article ID a009423, 2012.

[11] D. Ebrahimi-Fakhari, L. Wahlster, and P. J. McLean, "Protein degradation pathways in Parkinson's disease: curse or blessing," Acta Neuropathologica, vol. 124, no. 2, pp. 153–172, 2012.

[12] J. R. Mazzulli, F. Zhu, O. Isacson, L. Studer, and D. Krainc, "α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models," Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 7, pp. 1931–1936, 2016.

[13] A. Binolfi, R. M. Rasia, C. W. Bertoncini et al., "Interaction of α-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement," Journal of the American Chemical Society, vol. 128, no. 30, pp. 9893–9901, 2006.

[14] L. Breitdo and V. N. Uversky, "Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases," Metallomics, vol. 3, no. II, pp. 1163–1180, 2011.

[15] D. R. Brown, "Metal binding to alpha-synuclein peptides and its contribution to toxicity," Biochemical and Biophysical Research Communications, vol. 380, no. 2, pp. 377–381, 2009.

[16] L. L. Liu and K. J. Franz, "Phosphorylation-dependent metal binding by α-synuclein peptide fragments," Journal of Biological Inorganic Chemistry, vol. 12, no. 2, pp. 234–247, 2007.

[17] Y. Lu, M. Prudent, B. Fauvet, H. A. Lashuel, and H. H. Girault, "Phosphorylation of α-synuclein at Y125 and S129 alters its metal binding properties: implications for understanding the role of α-synuclein in the pathogenesis of Parkinson's disease and related disorders," ACS Chemical Neuroscience, vol. 2, no. 11, pp. 667–675, 2011.

[18] A. J. Hughes, S. E. Daniel, Y. Ben-Shlomo, and A. J. Lees, "The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service," Brain, vol. 125, no. 4, pp. 861–870, 2002.

[19] P. T. Kotzbauer, J. Q. Trojanowski, and V. M.-Y. Lee, "Lewy body pathology in Alzheimer's disease," Journal of Molecular Neuroscience, vol. 17, no. 2, pp. 225–232, 2001.

[20] M. G. Spillantini, M. L. Schmidt, V. M. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert, "α-synuclein in Lewy bodies," Nature, vol. 388, no. 6645, pp. 839–840, 1997.

[21] M. Goedert, "Alpha-synuclein and neurodegenerative diseases," Nature Reviews Neuroscience, vol. 2, no. 7, pp. 492–501, 2001.

[22] E. Rockenstein, L. A. Hansen, M. Mallory, J. Q. Trojanowski, D. Galasko, and E. Masliah, "Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease," Brain Research, vol. 914, no. 1-2, pp. 48–56, 2001.

[23] R. Jakes, M. G. Spillantini, and M. Goedert, "Identification of two distinct synucleins from human brain," FEBS Letters, vol. 345, no. 1, pp. 27–32, 1994.

[24] E. H. Norris, B. I. Giasson, and V. M.-Y. Lee, "α-Synuclein: Normal Function and Role in Neurodegenerative Diseases," Current Topics in Developmental Biology, vol. 60, pp. 17–54, 2004.

[25] J. P. Segrest, M. K. Jones, H. De Loof, C. G. Brouilllette, Y. V. Venkatatalapahati, and G. M. Anantharamaiah, "The amphi-pathic helix in the exchangeable apolipoproteins: a review of secondary structure and function," Journal of Lipid Research, vol. 33, no. 2, pp. 141–166, 1992.
[26] W. S. Davidson, A. Jonas, D. F. Clayton, and J. M. George, “Stabilization of α-synuclein secondary structure upon binding to synthetic membranes,” The Journal of Biological Chemistry, vol. 273, no. 16, pp. 9443–9449, 1998.

[27] K. Ueda, H. Fukushima, E. Masliyah et al., “Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 23, pp. 11282–11286, 1993.

[28] A. M. Bodles, D. J. S. Guthrie, B. Greer, and G. Brent Irvine, “Identification of the region of non-AB component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity,” Journal of Neurochemistry, vol. 78, no. 2, pp. 384–395, 2001.

[29] M. Okochi, J. Walter, A. Koyama et al., “Constitutive phosphorylation of the Parkinson's disease associated α- synuclein,” The Journal of Biological Chemistry, vol. 275, no. 1, pp. 390–397, 2000.

[30] M. P. Sang, Y. H. Han, T. D. Kim, H. P. Jeon, C.-H. Yang, and J. Kim, “Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of α-synuclein, a molecular chaperone,” The Journal of Biological Chemistry, vol. 277, no. 32, pp. 28512–28520, 2002.

[31] D. F. Clayton and J. M. George, “The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease,” Trends in Neuroscience, vol. 21, no. 6, pp. 249–254, 1998.

[32] M. C. Bennett, “The role of α-synuclein in neurodegenerative diseases,” Pharmacology & Therapeutics, vol. 105, no. 3, pp. 311–331, 2005.

[33] R. G. Perez, J. C. Waymire, E. Lin, J. J. Liu, F. Guo, and M. J. Zigmund, “A role for alpha-synuclein in the regulation of dopamine biosynthesis,” The Journal of Neuroscience, vol. 22, pp. 3090–3099, 2002.

[34] K. E. Larsen, Y. Schmitz, M. D. Troyer et al., “α-Synuclein over-expression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis,” The Journal of Neuroscience, vol. 26, no. 46, pp. 11915–11922, 2006.

[35] C. Wersinger and A. Sidhu, “Disruption of the interaction of α-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter,” Biochemistry, vol. 44, no. 41, pp. 13612–13624, 2005.

[36] D. E. Cabin, K. Shimazu, D. Murphy et al., “Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein,” The Journal of Neuroscience, vol. 22, no. 20, pp. 8797–8807, 2002.

[37] W. Dauer, N. Kholodilov, M. Vila et al., “Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 22, pp. 14524–14529, 2002.

[38] A. Abieliovich, Y. Schmitz, I. Fariñas et al., “Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system,” Neuron, vol. 25, no. 1, pp. 239–252, 2000.

[39] N. M. Bonini and B. I. Giasson, “Snaking the function of α-synuclein,” Cell, vol. 123, no. 3, pp. 359–361, 2005.

[40] J. Bürk, M. Sharma, T. Tsutsis, V. Buchman, M. R. Etherton, and T. C. Südhof, “α-Synuclein promotes SNARE-complex assembly in vivo and in vitro,” Science, vol. 329, no. 5999, pp. 1663–1667, 2010.

[41] J. E. Duda, V. M.-Y. Lee, and J. Q. Trojanowski, “Neuropathology of synuclein aggregates: New insights into mechanisms of neurodegenerative diseases,” Journal of Neuroscience Research, vol. 61, no. 2, pp. 121–127, 2000.

[42] R. A. Fredenburg, C. Rosspiglioni, R. K. Meray et al., “The impact of the E46K mutation on the properties of α-synuclein in its monomeric and oligomeric states,” Biochemistry, vol. 46, no. 24, pp. 7107–7118, 2007.

[43] M. Periquet, T. Fulga, L. Myllykangas, M. G. Schlossmacher, and M. B. Feany, “Aggregated α-synuclein mediates dopaminergic neurotoxicity in vivo,” The Journal of Neuroscience, vol. 27, no. 2, pp. 3338–3346, 2007.

[44] L. J. Hsu, Y. Sagara, A. Arroyo et al., “α-Synuclein promotes mitochondrial deficit and oxidative stress,” The American Journal of Pathology, vol. 157, no. 2, pp. 401–410, 2000.

[45] M. Hashimoto, K. Kawahara, P. Bar-On, E. Rockenstein, L. Crews, and E. Masliyah, “The role of α-synuclein assembly and metabolism in the pathogenesis of Lewy body disease,” Journal of Molecular Neuroscience, vol. 24, no. 3, pp. 343–352, 2004.

[46] M. A. Alim, Q.-L. Ma, K. Takeda et al., “Demonstration of a role for α-synuclein as a functional microtubule-associated protein,” Journal of Alzheimer's Disease, vol. 6, no. 4, pp. 435–442, 2004.

[47] D. A. Scott, I. Tabarean, Y. Tang, A. Cartier, E. Masliyah, and S. Roy, “A pathologic cascade leading to synaptic dysfunction in α-synuclein-induced neurodegeneration,” The Journal of Neuroscience, vol. 30, no. 24, pp. 8083–8095, 2010.

[48] F. Yang, Y.-P. Yang, C.-J. Mao et al., “Crosstalk between the proteasome system and autophagy in the clearance of α-synuclein,” Acta Pharmacologica Sinica, vol. 34, no. 5, pp. 674–680, 2013.

[49] Y. Machiya, S. Haru, S. Arawaka et al., “Phosphorylated α-Synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner,” The Journal of Biological Chemistry, vol. 285, no. 52, pp. 40732–40744, 2010.

[50] T. Vogiatzi, M. Xilouri, K. Vrekellis, and L. Stefanis, “Wild type α-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells,” The Journal of Biological Chemistry, vol. 283, no. 35, pp. 23542–23556, 2008.

[51] A. M. Cuervo, L. Stafanis, R. Fredenburg, P. T. Lansbury, and D. Sulzer, “Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy,” Science, vol. 305, no. 5688, pp. 1292–1295, 2004.

[52] J. L. Webb, B. Ravikumar, J. Atkins, J. N. Skepper, and D. C. Rubinsztein, “α-Synuclein is degraded by both autophagy and the proteasome,” The Journal of Biological Chemistry, vol. 278, no. 27, pp. 25009–25013, 2003.

[53] M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., “Mutation in the α-synuclein gene identified in families with Parkinson's disease,” Science, vol. 276, pp. 3521, pp. 2045–2047, 1997.

[54] R. Krüger, W. Kuhn, T. Müller et al., “Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease,” Nature Genetics, vol. 18, no. 2, pp. 106–108, 1998.

[55] J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban et al., “The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia,” Annals of Neurology, vol. 55, no. 2, pp. 164–173, 2004.

[56] S. Appel-Cresswell, C. Vilarino-Guell, M. Encarnacion et al., “Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson disease,” Movement Disorders, vol. 28, no. 6, pp. 811–813, 2013.

[57] S. Lesage, M. Anheim, F. Letournel et al., “G31D α-synuclein mutation causes a novel Parkinsonian-pyramidal syndrome,” Annals of Neurology, vol. 73, no. 4, pp. 459–471, 2013.

[58] M. Chartier-Harlin, J. Kachergus, C. Roumier et al., “α-synuclein locus duplication as a cause of familial Parkinson's disease,” The Lancet, vol. 364, no. 9440, pp. 1167–1169, 2004.
A. B. Singleton, M. Farrer, J. Johnson et al., “α-synuclein locus triplication causes Parkinson’s disease,” Science, vol. 302, no. 5646, article 841, 2003.

J. P. Anderson, D. E. Walker, J. M. Goldstein et al., “Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease,” The Journal of Biological Chemistry, vol. 281, no. 40, pp. 29739–29752, 2006.

T. Hunter, “Signaling—2000 and beyond,” Cell, vol. 100, no. 1, pp. 113–127, 2000.

A. A. Bielska and N. J. Zondlo, “Hyperphosphorylation of tau induces local polyproline II helix,” Biochemistry, vol. 45, no. 17, pp. 5527–5537, 2006.

N. Errington and A. J. Doig, “A phosphoserine-lysine salt bridge within an α-helical peptide, the strongest α-helix side-chain interaction measured to date,” Biochemistry, vol. 44, no. 20, pp. 7553–7558, 2005.

R. S. Signarvic and W. F. DeGrado, “De novo design of a molecular switch: Phosphorylation-dependent association of designed peptides,” Journal of Molecular Biology, vol. 334, no. 1, pp. 1–12, 2003.

A. Tholey, A. Lindemann, V. Kinzel, and J. Reed, “Direct effects of phosphorylation on the preferred backbone conformation of peptides: A nuclear magnetic resonance study,” Biophysical Journal, vol. 76, no. 11, pp. 76–87, 1999.

L. Chen and M. B. Feany, “α-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease,” Nature Neuroscience, vol. 8, no. 5, pp. 657–663, 2005.

B.-H. Ahn, H. Rhim, Y.-M. Shi Yeon Kim et al., “α-synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase d activation in human embryonic kidney-293 cells,” The Journal of Biological Chemistry, vol. 277, no. 14, pp. 12334–12342, 2002.

T. Nakamura, H. Yamashita, T. Takahashi, and S. Nakamura, “Activated Fyn phosphorylates α-synuclein at tyrosine residue 125,” Biochemical and Biophysical Research Communications, vol. 280, no. 4, pp. 1085–1092, 2001.

C. E. Ellis, P. L. Schwartzberg, T. L. Grider, D. W. Fink, and R. L. Nussbaum, “α-Synuclein Is Phosphorylated by Members of the Src Family of Protein-tyrosine Kinases,” The Journal of Biological Chemistry, vol. 276, no. 6, pp. 3879–3884, 2001.

H. Sato, S. Arawaka, S. Haru et al., “Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson’s disease,” The Journal of Neuroscience, vol. 31, no. 46, pp. 16884–16894, 2011.

H. Sato, T. Kato, and S. Arawaka, “The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson’s disease: A review of in vivo models,” Reviews in the Neurosciences, vol. 24, no. 2, pp. 115–123, 2013.

K. J. Inglis, D. Chereau, E. F. Brigham et al., “Polo-like kinase 2 (PLK2) phosphorylates α-synuclein at serine 129 in central nervous system,” The Journal of Biological Chemistry, vol. 284, no. 5, pp. 2598–2602, 2009.

A. N. Pronin, A. J. Morris, A. Surguchov, and J. L. Benovic, “Synucleins are a novel class of substrates for G protein–coupled receptor kinases,” The Journal of Biological Chemistry, vol. 275, no. 34, pp. 26535–26522, 2000.

J. Kosten, A. Binolfi, M. Stuiver et al., “Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event,” ACS Chemical Neuroscience, vol. 5, no. 12, pp. 1203–1208, 2014.

S. Zhang, J. Xie, Y. Xia et al., “LKB1/Mnk2a is a new kinase of alpha synuclein phosphorylation mediating neurodegeneration,” Scientific Reports, vol. 5, Article ID 12564, 2015.

W. W. Smith, R. L. Margolis, X. Li et al., “α-synuclein phosphorylation enhances cosinophilic cytoplasmic inclusion formation in SH-SY5Y cells,” The Journal of Neuroscience, vol. 25, no. 23, pp. 5544–5552, 2005.

M. Takahashi, L.-W. Ko, J. Kukathalingal, P. Jiang, D. Sevlever, and S.-H. C. Yen, “Oxidative stress-induced phosphorylation, degradation and aggregation of α-synuclein are linked to upregulated CK2 and cathepsin D,” European Journal of Neuroscience, vol. 26, no. 4, pp. 863–874, 2007.

N. Sugeno, A. Takeda, T. Hasegawa et al., “Serine 129 phosphorylation of α-synuclein induces unfolded protein response-mediated cell death,” The Journal of Biological Chemistry, vol. 283, no. 34, pp. 23179–23188, 2008.

M. Martinez-Vicente, Z. Tallocczy, S. Kaushik et al., “Dopamine-modified α-synuclein blocks chaperone-mediated autophagy,” The Journal of Clinical Investigation, vol. 118, no. 2, pp. 777–778, 2008.

S. K. Mak, A. L. McCormack, A. B. Manning-Bog, A. M. Cuervo, and D. A. Di Monte, “Lysosomal degradation of α-synuclein in vivo,” The Journal of Biological Chemistry, vol. 285, no. 18, pp. 13621–13629, 2010.

R. Perfeito, D. F. Lázaro, T. F. Outeiro, and A. C. Rego, “Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells,” Molecular and Cellular Neuroscience, vol. 62, pp. 51–59, 2014.

K.-Y. Chau, H. L. Ching, A. H. V. Schapira, and J. M. Cooper, “Relationship between alpha synuclein phosphorylation, pro teaseomal inhibition and cell death: Relevance to Parkinson’s disease pathogenesis,” Journal of Neurochemistry, vol. 110, no. 3, pp. 1005–1013, 2009.

A. N. Pronin, C. V. Carman, and J. L. Benovic, “Structure-function analysis of G protein–coupled receptor kinase-5: Role of the carboxyl terminus in kinase regulation,” The Journal of Biological Chemistry, vol. 273, no. 47, pp. 31510–31518, 1998.

T. T. Chuang, L. Paolucci, and A. De Blasi, “Inhibition of G protein–coupled receptor kinase subtypes by Ca2+/calmodulin,” The Journal of Biological Chemistry, vol. 271, no. 45, pp. 28691–28696, 1996.

G. S. Nübling, J. Levin, B. Bader et al., “Modelling Ser129 phosphorylation inhibits membrane binding of pore-forming alpha-synuclein oligomers,” PLoS ONE, vol. 9, no. 6, Article ID e89806, 2014.

T. Kuwahara, R. Tonegawa, G. Ito, S. Mitani, and T. Iwatsubo, “Phosphorylation of α-synuclein protein at ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans,” The Journal of Biological Chemistry, vol. 287, no. 10, pp. 7098–7109, 2012.

V. Sancenon, S.-A. Lee, C. Patrick et al., “Suppression of α-synuclein toxicity and vesicle trafficking defects by phosphorylation at SI29 in yeast depends on genetic context,” Human Molecular Genetics, vol. 21, no. 11, Article ID dds058, pp. 2432–2449, 2012.

B. Wu, Q. Liu, C. Duan et al., “Phosphorylation of α-synuclein upregulates tyrosine hydroxylase activity in MN9D cells,” Acta Histochemica, vol. 113, no. 1, pp. 32–35, 2011.

K. E. Paleologou, A. W. Schmid, C. C. Rospiroldi et al., “Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of α-synuclein,” The Journal of Biological Chemistry, vol. 283, no. 24, pp. 16895–16905, 2008.
N. R. McFarland, Z. Fan, K. Xu et al., "α-Synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease," *Journal of Neuropathology & Experimental Neurology*, vol. 68, no. 5, pp. 515–524, 2009.

O. S. Gorbatyuk, S. Li, L. F. Sullivan et al., "The phosphorylation state of Ser-129 in human α-synuclein determines neurodegeneration in a rat model of Parkinson disease," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 2, pp. 763–768, 2008.

K. E. Paleologou, A. Oueslati, G. Shakked et al., "Phosphorylation at S87 is enhanced in synucleinopathies, inhibits α-synuclein oligomerization, and influences synuclein-membrane interactions," *The Journal of Neuroscience*, vol. 30, no. 9, pp. 3184–3190, 2010.

M. Yamada, T. Iwatsubo, Y. Mizuno, and H. Mochizuki, "Over-expression of α-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α-synuclein and activation of caspase-9: Resemblance to pathogenic changes in Parkinson's disease," *Journal of Neurochemistry*, vol. 91, no. 2, pp. 451–461, 2004.

E. A. Waxman and B. I. Giasson, "Specificity and regulation of casein kinase-mediated phosphorylation of α-synuclein," *Journal of Neuropathology & Experimental Neurology*, vol. 67, no. 5, pp. 402–416, 2008.

H. Fujiwara, M. Hasegawa, N. Dohmae et al., "α-synuclein is phosphorylated in synucleinopathy lesions," *Nature Cell Biology*, vol. 4, no. 2, pp. 160–164, 2002.

M. Hasegawa, H. Fujiwara, T. Nonaka et al., "Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions," *The Journal of Biological Chemistry*, vol. 277, no. 50, pp. 49071–49076, 2002.

Y. Wang, M. Shi, and K. A. Chung, "Phosphorylated α-synuclein in Parkinson’s disease," *Science Translational Medicine*, vol. 4, no. 121, Article ID 121ra20, 2012.

N. K. Majbour, N. N. Vaikath, K. D. Van Dijk et al., "Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease," *Molecular Neurodegeneration*, vol. 11, no. 1, article no. 7, 2016.

L. L. Liu and K. J. Franz, "Phosphorylation of an α-synuclein peptide fragment enhances metal binding," *Journal of the American Chemical Society*, vol. 127, no. 27, pp. 9662-9665, 2005.

A. Garcia-Garcia, H. Rodriguez-Rocha, N. Madayiputhiya, A. Pappa, M. I. Panayiotidis, and R. Franco, "Biomarkers of protein oxidation in human disease," *Current Molecular Medicine*, vol. 12, no. 6, pp. 681–697, 2012.

A. Santner and V. N. Uversky, "Metalloproteomics and metal toxicology of α-synuclein," *Metallomics*, vol. 2, no. 6, pp. 378–392, 2010.

V. N. Uversky, J. Li, and A. L. Fink, "Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein: A possible molecular link between Parkinson’s disease and heavy metal exposure," *The Journal of Biological Chemistry*, vol. 276, no. 47, pp. 44284–44296, 2001.

R. M. Rasia, C. W. Bertocnini, D. Marsh et al., "Structural characterization of copper(II) binding to α-synuclein: insights into the bioinorganic chemistry of Parkinson’s disease," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 12, pp. 4294–4299, 2005.

A. Binolfi, L. Quintanar, C. W. Bertocnini, C. Griesinger, and C. O. Fernández, "Bioinorganic chemistry of copper coordination to alpha-synuclein: Relevance to Parkinson’s disease," *Coordination Chemistry Reviews*, vol. 256, no. 19-20, pp. 2188–2201, 2012.

S. R. Paik, H.-J. Shin, J.-H. Lee, C.-S. Chang, and J. Kim, "Copper(II)-induced self-oligomerization of α-synuclein," *Biochemical Journal*, vol. 340, no. 3, pp. 821–828, 1999.

Y. Xiao, D. Chen, X. Zhang et al., "Molecular study on copper-mediated tumor proteasome inhibition and cell death," *International Journal of Oncology*, vol. 37, pp. 81–87, 2010.

N. K. Y. Wee, D. C. Weinstein, S. T. Fraser, and S. J. Assinder, "The mammalian copper transporters CTR1 and CTR2 and their roles in development and disease," *The International Journal of Biochemistry & Cell Biology*, vol. 45, no. 5, pp. 960–963, 2013.